We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

argen-x Announces Non-Exclusive License with Biowa for Potelligent® Technology

News   Jul 27, 2011

 
argen-x Announces Non-Exclusive License with Biowa for Potelligent® Technology
 
 
 

RELATED ARTICLES

New Study of HIV Vaccine Shows Promising Results Across Strains

News

Using the same RV 144 HIV vaccine employed in Thailand, a new study has evaluated whether the vaccine-induced immune responses to RV 144 are similar in a South African cohort.

READ MORE

Mutating Ebola Virus Protein Works as a Vaccine to Protect Animals From Infection

News

Creating mutations in a key Ebola virus protein that helps the deadly virus escape from the body's defenses can make the virus unable to produce sickness and activate protective immunity in the infected host, according to a study by the Institute for Biomedical Sciences at Georgia State University.

READ MORE

Alzheimer's Risk Gene Impairs Brain's Immune Cells

News

A study carried out with a new human stem cell-derived model reveals that the most prevalent genetic risk factor of Alzheimer's disease (AD), apolipoprotein E4 (APOE4), impairs the function of human brain immune cells, microglia. These findings pave the way for new, effective treatment approaches for AD. The results were published in Stem Cell Reports.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE